| Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | ||
|---|---|---|---|---|---|---|
Assets | ||||||
Current assets: | ||||||
Cash | ||||||
123,530 | 1,610 | 1,911 | 6,985 | 325 | ||
Prepaid expenses | ||||||
44 | 152 | 162 | 2,632 | - | ||
Income tax receivable | ||||||
- | - | - | 49 | - | ||
Value-added tax receivable | ||||||
2,996 | - | - | 2,913 | - | ||
Total current assets | ||||||
126,570 | 1,762 | 2,073 | 12,579 | 325 | ||
Property and equipment, net | ||||||
49 | - | - | 54 | - | ||
Deferred offering costs | ||||||
- | - | - | 1,195 | - | ||
Deferred offering costs | ||||||
- | - | - | - | 80 | ||
Cash and marketable securities held in Trust Account | ||||||
- | 116,024 | 115,341 | - | - | ||
Total assets | ||||||
126,619 | 117,787 | 117,415 | 13,828 | 405 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities: | ||||||
Accounts payable | ||||||
2,812 | - | - | 206 | - | ||
Accrued expenses | ||||||
8,705 | 306 | 24 | 6,225 | 0 | ||
Due to Roivant Sciences Ltd. | ||||||
3,134 | - | - | 58 | - | ||
Accrued offering costs | ||||||
- | - | - | - | 80 | ||
Income tax payable | ||||||
106 | 31 | 66 | - | - | ||
Promissory note - related party | ||||||
- | - | - | - | 300 | ||
Total Current Liabilities | ||||||
- | 337 | 91 | - | 380 | ||
Deferred underwriting fee payable | ||||||
- | 4,025 | 4,025 | - | - | ||
Total liabilities | ||||||
14,757 | 4,362 | 4,116 | 6,489 | 380 | ||
Common stock subject to possible redemption, 10,842,452 shares at redemption value | ||||||
- | 108,424 | 108,299 | - | - | ||
Stockholders' equity: | ||||||
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 56,455,376 shares issued and 54,655,376 shares outstanding at December 31, 2019 and 489,066,238 shares authorized, 38,590,381 shares issued and outstanding at March 31, 2019 | ||||||
5 | 0 | 0 | 4 | 0 | ||
Common stock subscribed | ||||||
- | - | - | 3 | - | ||
Additional paid-in capital | ||||||
182,679 | 4,692 | 4,817 | 31,830 | 24 | ||
Accumulated other comprehensive (loss) income | ||||||
-147 | - | - | 346 | - | ||
Accumulated deficit | ||||||
-70,675 | 306 | 181 | -24,838 | -0 | ||
Total stockholders' equity | ||||||
111,862 | 5,000 | 5,000 | 7,339 | 24 | ||
Total liabilities and stockholders' equity | ||||||
126,619 | 117,787 | 117,415 | 13,828 | 405 | ||